Fig. 8

CDN inhibits OS tumor growth in vivo. (A) Immunodeficient nude mice were subcutaneously implanted with MG63 cells. Mice were randomly divided into 2 groups, and DMSO or CDN was administered every 5 days for 4 times. Tumor volumes were detected every 5 days. Left, tumor images taken on day 20. Right, tumor volumes were measured at different time points (n = 5), and tumor weight was measured at 20 days. (B) Immunohistochemical analysis of Ki67, CD133, LC3, and β-catenin expression in MG63 xenografts from DMSO or CDN-treated mice. Scale bar:100μM.